Communiqués DocMorris AG

Actions

ROSE

CH0042615283

Pharmacies

Temps réel estimé Cboe Europe 15:05:20 07/09/2026			Varia. 5j.	Varia. 1 janv.
10,79 ^CHF	0,00 %		-0,55 %	+82,18 %

03/09	DocMorris AG : Jefferies toujours neutre sur le dossier	ZD
26/08	Stadler et Inventiva en forme, Ambu et OVH en sortie de route

Communiqués

19/08	DocMorris : Half-Year Results Presentation 2026	PU
19/08	DocMorris : with strong growth momentum in Rx and Digital Services in the first half of the year and guidance increase	PU
19/08	DocMorris with strong growth momentum in Rx and Digital Services in the first half of the year and guidance increase	EQ
15/07	DocMorris reports strong revenue growth of 15% in the second quarter; Rx grows by 46% and Digital Services by 80%	EQ
25/06	DocMorris announces accelerated implementation of its “AI-First” strategy; positive cost savings of at least CHF 15 million per year	EQ
18/05	DocMorris : Governance presentation	PU
13/05	DocMorris : AGM voting results 2026	PU
12/05	2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy	EQ
16/04	DocMorris : AGM Invitation 2026	PU
16/04	DocMorris : Q1 2026 Trading Update Presentation	PU
16/04	DocMorris publishes invitation to the Annual General Meeting	EQ
16/04	DocMorris achieves strong revenue growth in Q1 2026 – on track for EBITDA break-even	EQ
14/04	DocMorris : enhances its leading AI-powered health platform by partnering with Hello Inside to address metabolic healthcare	PU
19/03	DocMorris and Google partner to advance one of Europe’s leading AI-powered digital health platform	EQ
19/03	DocMorris achieves 2025 targets – focus on profitability, growth and expansion of digital health platform	EQ
19/03	DocMorris : Annual Report 2025	PU
19/03	DocMorris : Annual Results Presentation 2025	PU
03/03	DocMorris AG announces changes to its Board of Directors	EQ
12/02	DocMorris and Infermedica simplify health: from symptoms to solutions with the AI health companion	PU
02/02	Early redemption of the 6.875% Convertible Bonds due 2026	EQ
26/01	DocMorris repurchases convertible bonds maturing in 2026 with a nominal value of around CHF 14.4 million	EQ
20/01	DocMorris achieves 11.1 per cent revenue growth in 2025 – strong fourth quarter	EQ
13/11	DocMorris announces the results of the tender offer for its Outstanding Convertible Bonds due 2026	EQ
06/11	DocMorris announces the start of the tender offer period for its Outstanding Convertible Bonds due 2026	EQ
22/10/25	DocMorris successfully completes the placement of CHF 49.6 million Convertible Bonds due 2028	EQ